A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1944-446X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS ; volume:35 ; number:1 ; day:28 ; month:10 ; year:2016 ; pages:1-3 ; date:12.2016
Chinese journal of cancer ; 35, Heft 1 (28.10.2016), 1-3, 12.2016
- Creator
-
Pang, Xiufeng
- Contributor
-
Liu, Mingyao
SpringerLink (Online service)
- DOI
-
10.1186/s40880-016-0154-7
- URN
-
urn:nbn:de:1111-201611251255
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pang, Xiufeng
- Liu, Mingyao
- SpringerLink (Online service)
Other Objects (12)
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Target Mutant KRAS with Molecular Glue
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Current therapy of KRAS-mutant lung cancer
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Targeting mutant KRAS in pancreatic cancer: futile or promising?
Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer
Targeting a defective DNA damage response in KRAS-mutant adenocarcinomas
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Target Mutant KRAS with Molecular Glue
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Current therapy of KRAS-mutant lung cancer
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Targeting mutant KRAS in pancreatic cancer: futile or promising?
Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer
Targeting a defective DNA damage response in KRAS-mutant adenocarcinomas
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Target Mutant KRAS with Molecular Glue
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Current therapy of KRAS-mutant lung cancer
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Targeting mutant KRAS in pancreatic cancer: futile or promising?
Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer
Targeting a defective DNA damage response in KRAS-mutant adenocarcinomas
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer